Clinical trial
Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma
NCT00111774 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00111774 |
|---|---|
| Title | Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma |
| Official title | An Open Label Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of ABX-EGF in Patients With Metastatic Colorectal Carcinoma |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer, Carcinoma |
| Intervention type | Drug |
| Interventions | ABX-EGF |
| Enrollment | 150 |
| Start date | Mar 1, 2002 |
| First posted | May 26, 2005 |
| Last update posted | May 14, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: